Skip to main content
Top

09-08-2018 | Rheumatoid arthritis | Review | Article

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Journal: Current Rheumatology Reports

Authors: Sizheng Zhao, Laura Chadwick, Eduardo Mysler, Robert J. Moots

Publisher: Springer US

Abstract

Purpose of Review

Adalimumab is one of the top-selling drugs worldwide. Its imminent patent expiration has seen the emergence of numerous biosimilar agents. In this article, we recap the evidence from bio-originator trials in rheumatoid arthritis (RA) to provide context for a critical review of biosimilar trial data.

Recent Findings

Currently, three adalimumab biosimilars are approved in Europe and/or the USA: Amgen’s ABP 501 (AMJEVITA/Solymbic), Boehringer Ingelheim’s BI 695501 (Cyltezo) and Samsung Bioepis’s SB5 (Imraldi). All three agents met their pre-specified equivalence criteria. Subtle differences in adverse events and clinical responses between the reference and biosimilar products were noted.

Summary

The introduction of adalimumab biosimilars will offer exciting opportunities in improving treatment access and increasing treatment options for RA and other licensed indications. Real-world data will further provide assurances on efficacy as well as safety.
Literature
1.
Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. PharmacoEconomics. 2004;22(2 Suppl 1):1–12.CrossRefPubMed
2.
Markusse IM, Akdemir G, Dirven L, Goekoop-Ruiterman YP, van Groenendael JH, Han KH, et al. Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial. Ann Intern Med. 2016;164(8):523–31. https://​doi.​org/​10.​7326/​M15-0919.CrossRefPubMed
3.
Sparks JA, Lin TC, Camargo CA Jr, Barbhaiya M, Tedeschi SK, Costenbader KH, et al. Rheumatoid arthritis and risk of chronic obstructive pulmonary disease or asthma among women: a marginal structural model analysis in the Nurses’ Health Study. Semin Arthritis Rheum. 2018;47(5):639–48. https://​doi.​org/​10.​1016/​j.​semarthrit.​2017.​09.​005.CrossRefPubMed
4.
Lundkvist J, Kastang F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ. 2008;8(Suppl 2):S49–60. https://​doi.​org/​10.​1007/​s10198-007-0088-8.CrossRefPubMed
5.
Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77. https://​doi.​org/​10.​1136/​annrheumdis-2016-210715.CrossRefPubMed
6.
Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(5):670–5. https://​doi.​org/​10.​1136/​ard.​2006.​062497.CrossRefPubMed
7.
Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFalpha inhibitors and rituximab. Ann Rheum Dis. 2015;74(2):415–21. https://​doi.​org/​10.​1136/​annrheumdis-2013-204021.CrossRefPubMed
8.
AbbVie. AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results 2018. https://​news.​abbvie.​com/​news/​abbvie-reports-full-year-and-fourth-quarter-2017-financial-results.​htm. Accessed April 2018.
9.
10.
World Health Organization. Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs). 2016. http://​www.​who.​int/​biologicals/​biotherapeutics/​similar_​biotherapeutic_​products/​en/​. March 2017.
11.
Salfield J, Kaymakcalan J, Tracey D, Roberts A, Kamen R. Generation of fully human anti-TNF antibody D2E7. Arthritis Rheum. 1998;41(9):S57-S.
12.
Cvetkovic RS, Scott LJ. Adalimumab: a review of its use in adult patients with rheumatoid arthritis. BioDrugs. 2006;20(5):293–311.CrossRefPubMed
13.
Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study. PLoS One. 2017;12(4):e0175207. https://​doi.​org/​10.​1371/​journal.​pone.​0175207.CrossRefPubMedPubMedCentral
14.
Keystone EC, Breedveld FC, van der Heijde D, Landewe R, Florentinus S, Arulmani U, et al. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. J Rheumatol. 2014;41(1):5–14. https://​doi.​org/​10.​3899/​jrheum.​130543.CrossRefPubMed
15.
Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis. 2006;65(6):753–9. https://​doi.​org/​10.​1136/​ard.​2005.​044404.CrossRefPubMed
16.
van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63(5):508–16. https://​doi.​org/​10.​1136/​ard.​2003.​013052.CrossRefPubMedPubMedCentral
17.
Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26–37. https://​doi.​org/​10.​1002/​art.​21519.CrossRefPubMed
18.
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35–45. https://​doi.​org/​10.​1002/​art.​10697.CrossRefPubMed
19.
Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50(5):1400–11. https://​doi.​org/​10.​1002/​art.​20217.CrossRefPubMed
20.
Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003;30(12):2563–71.PubMed
21.
Smolen JS, Burmester GR, Combe B, Curtis JR, Hall S, Haraoui B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet. 2016;388(10061):2763–74. https://​doi.​org/​10.​1016/​S0140-6736(16)31651-8.CrossRefPubMed
22.
Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390(10093):457–68. https://​doi.​org/​10.​1016/​S0140-6736(17)31618-5.CrossRefPubMed
23.
Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013;65(1):28–38. https://​doi.​org/​10.​1002/​art.​37711.CrossRefPubMedPubMedCentral
24.
Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet. 2016;388(10041):239–47. https://​doi.​org/​10.​1016/​S0140-6736(16)00380-9.CrossRefPubMed
25.
Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ. 2009;181(11):787–96. https://​doi.​org/​10.​1503/​cmaj.​091391.CrossRefPubMedPubMedCentral
26.
Jorgensen TS, Turesson C, Kapetanovic M, Englund M, Turkiewicz A, Christensen R, et al. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: a prospective observational study of patients registered in the south Swedish SSATG registry. PLoS One. 2017;12(2):e0169946. https://​doi.​org/​10.​1371/​journal.​pone.​0169946.CrossRefPubMedPubMedCentral
27.
Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22–32. https://​doi.​org/​10.​1002/​art.​27227.CrossRefPubMed
28.
Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76(5):840–7. https://​doi.​org/​10.​1136/​annrheumdis-2016-210310.CrossRefPubMed
29.
Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541–50. https://​doi.​org/​10.​1016/​S0140-6736(13)60250-0.CrossRefPubMed
30.
Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen ML, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652–62. https://​doi.​org/​10.​1056/​NEJMoa1608345.CrossRefPubMed
31.
Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. 2015. https://​www.​fda.​gov/​Drugs/​GuidanceComplian​ceRegulatoryInfo​rmation/​Guidances/​ucm290967.​htm. March 2017.
32.
European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2015 http://​www.​ema.​europa.​eu/​ema/​index.​jsp?​curl=​pages/​regulation/​general/​general_​content_​000408.​jsp. March 2017.
33.
Genovese MC, Glover J, Matsunaga N, Chisholm D, Alten R. Efficacy, safety and immunogenicity in randomized, double-blind (DB) and open label extension (OLE) studies comparing FKB327, an adalimumab biosimilar, with the adalimumab reference product (Humira (R); RP) in patients (pts) with active rheumatoid arthritis (RA). Arthritis Rheumatol. 2017;69:2.
34.
Alten R, Glover J, Matsunaga N, Chisholm D, Genovese M. Efficacy and safety results of a phase iii study comparing FKB327, an adalimumab biosimilar, with the adalimumab reference product in patients with active rheumatoid arthritis. Ann Rheum Dis. 2017;76:59. https://​doi.​org/​10.​1136/​annrheumdis-2017-eular.​2220.CrossRef
35.
Blauvelt A, Lacour JP, Fowler J, Schuck E, Jauch-Lembach J, Balfour A, et al. Long-term efficacy, safety and immunogenicity results from a randomized, double-blind, phase III confirmatory efficacy and safety study comparing GP2017, a proposed biosimilar, with reference adalimumab. Arthritis Rheum. 2017;69:4.
36.
Sandoz. Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency. 2017. https://​www.​sandoz.​com/​news/​media-releases/​sandoz-proposed-biosimilars-adalimumab-and-infliximab-accepted-regulatory-review. Apri 2018.
37.
Jamshidi A, Gharibdoost F, Vojdanian M, Soroosh SG, Soroush M, Ahmadzadeh A, et al. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA(R)) to the reference product (Humira(R)) in patients with active rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):168. https://​doi.​org/​10.​1186/​s13075-017-1371-4.CrossRefPubMedPubMedCentral
38.
Jani RH, Gupta R, Bhatia G, Rathi G, Ashok Kumar P, Sharma R, et al. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis. 2016;19(11):1157–68. https://​doi.​org/​10.​1111/​1756-185X.​12711.CrossRefPubMed
39.
Business Standard. Torrent launches world's second biosimilar of generic auto-immune drug. 2016. http://​www.​business-standard.​com/​article/​companies/​torrent-launches-world-s-second-biosimilar-of-generic-auto-immune-drug-116011100615_​1.​html. April 2018.
40.
Kaur P, Chow V, Zhang N, Moxness M, Kaliyaperumal A, Markus R. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Ann Rheum Dis. 2017;76(3):526–33. https://​doi.​org/​10.​1136/​annrheumdis-2015-208914.CrossRefPubMed
41.
Velayudhan J, Chen YF, Rohrbach A, Pastula C, Maher G, Thomas H, et al. Demonstration of functional similarity of proposed biosimilar ABP 501 to adalimumab. BioDrugs. 2016;30(4):339–51. https://​doi.​org/​10.​1007/​s40259-016-0185-2.CrossRefPubMedPubMedCentral
42.
Liu J, Eris T, Li C, Cao S, Kuhns S. Assessing analytical similarity of proposed Amgen biosimilar ABP 501 to adalimumab. BioDrugs. 2016;30(4):321–38. https://​doi.​org/​10.​1007/​s40259-016-0184-3.CrossRefPubMedPubMedCentral
43.
Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017;76(6):1093–102. https://​doi.​org/​10.​1016/​j.​jaad.​2016.​12.​014.CrossRefPubMed
44.
• Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76(10):1679–87. https://​doi.​org/​10.​1136/​annrheumdis-2016-210459. This is a large, high quality randomised controlled trial of an adalimumab biosimilar CrossRefPubMed
47.
Wynne C, Altendorfer M, Sonderegger I, Gheyle L, Ellis-Pegler R, Buschke S, et al. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE(R)-PK) in healthy subjects. Expert Opin Investig Drugs. 2016;25(12):1361–70. https://​doi.​org/​10.​1080/​13543784.​2016.​1255724.CrossRefPubMed
48.
• Cohen SB, Alonso-Ruiz A, Klimiuk PA, Lee EC, Peter N, Sonderegger I, et al. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis. 2018; https://​doi.​org/​10.​1136/​annrheumdis-2017-212245. This is large, high quality randomised controlled trial of an adalimumab biosimilar
50.
Shin D, Lee Y, Kim H, Körnicke T, Fuhr R. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers. J Clin Pharm Ther. 2017;42:672–8.CrossRefPubMed
51.
• Weinblatt ME, Baranauskaite A, Niebrzydowski J, Dokoupilova E, Zielinska A, Jaworski J, et al. Phase III randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis. Arthritis Rheum. 2018;70(1):40–8. https://​doi.​org/​10.​1002/​art.​40336. This is large, high quality randomised controlled trial of an adalimumab biosimilar CrossRef
53.
Griffiths CEM, Thaci D, Gerdes S, Arenberger P, Pulka G, Kingo K, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176(4):928–38. https://​doi.​org/​10.​1111/​bjd.​15152.CrossRefPubMed
54.
Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014–22. https://​doi.​org/​10.​1056/​NEJMoa030409.CrossRefPubMed
55.
Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367(9504):29–35. https://​doi.​org/​10.​1016/​S0140-6736(05)67763-X.CrossRefPubMed
56.
Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–15. https://​doi.​org/​10.​1016/​j.​jaad.​2007.​09.​010.CrossRefPubMed
57.
Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558–66. https://​doi.​org/​10.​1111/​j.​1365-2133.​2007.​08315.​x.CrossRefPubMed
58.
Moots RJ, Curiale C, Petersel D, Rolland C, Jones H, Mysler E. Efficacy and safety outcomes for originator TNF inhibitors and biosimilars in rheumatoid arthritis and psoriasis trials: a systematic literature review. BioDrugs. 2018; https://​doi.​org/​10.​1007/​s40259-018-0283-4.CrossRefPubMed
59.
Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374(9685):210–21. https://​doi.​org/​10.​1016/​S0140-6736(09)60506-7.CrossRefPubMed
60.
Karlsson JA, Kristensen LE, Kapetanovic MC, Gulfe A, Saxne T, Geborek P. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology. 2008;47(4):507–13. https://​doi.​org/​10.​1093/​rheumatology/​ken034.CrossRefPubMed
61.
• Moots R, Azevedo V, Coindreau JL, Dorner T, Mahgoub E, Mysler E, et al. Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. Curr Rheumatol Rep. 2017;19(6):37. https://​doi.​org/​10.​1007/​s11926-017-0658-4. Practical discussion on switching between bio-originator and biosimilars CrossRefPubMedPubMedCentral
62.
Weinblatt ME, Baranauskaite A, Dokoupilova E, Zielinska A, Jaworski J, Racewicz A, et al. Switching from reference adalimumab to SB5 (adalimumab biosimilar) in patients with rheumatoid arthritis: fifty-two-week phase III randomized study results. Arthritis Rheumatol. 2018;70:832–40. https://​doi.​org/​10.​1002/​art.​40444.CrossRefPubMedPubMedCentral
63.
Cohen S, Pablos JL, Wang H, Muller GA, Kivitz A, Matsumoto A, et al. ABP 501 biosmilar to adalimumab: final safety, immunogenicity, and efficacy results from an open-label extension study. Ann Rheum Dis. 2017;76:834–5. https://​doi.​org/​10.​1136/​annrheumdis-2017-eular.​3288.CrossRef
64.
Cohen S, Pablos JL, Zhang N, Rizzo W, Muller G, Padmanaban D, et al. ABP 501 long-term safety/efficacy: interim results from an open-label extension study. Arthritis Rheumatol. 2016;68:2.